Logistic regression model 1 for the positivity rate
| ALK | EGFR | PD-L1 | ||||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Sample type* (ref. biopsy) | ||||||
| Cell block | 0.77 (0.31 to 1.60) | 0.513 | 0.95 (0.66 to 1.36) | 0.802 | 1.00 (0.72 to 1.37) | 0.984 |
| FNA | 1.72 (0.59 to 4.04) | 0.261 | 1.20 (0.76 to 1.84) | 0.417 | 0.86 (0.28 to 2.60) | 0.785 |
| Surgical piece | 1.13 (0.62 to 1.96) | 0.682 | 0.94 (0.69 to 1.25) | 0.661 | 0.80 (0.63 to 1.03) | 0.081 |
| Blood | – | – | 1.54 (0.85 to 2.65) | 0.134 | – | – |
| Others | 1.48 (0.60 to 3.12) | 0.341 | 1.47 (0.96 to 2.19) | 0.068 | 1.17 (0.73 to 1.88) | 0.515 |
| NSCLC-NOS (ref. adenocarcinoma) | 0.85 (0.33 to 1.83) | 0.707 | 0.16 (0.07 to 0.33) | <0.001 | 1.20 (0.87 to 1.66) | 0.256 |
| Hosmer-Lemeshow, p value | 0.997 | 0.995 | 0.997 | |||
| AUROC (95% CI) | 0.543 (0.486 to 0,601) | 0.565 (0.538 to 0.592) | 0.526 (0.503 to 0.549) | |||
The results of the Hosmer-Lemeshow test and the AUROC are in italics to differentiate them from the ORs.
*Category ‘others’ includes blood samples for ALK and PD-L1 models.
ALK, anaplastic lymphoma kinase; AUROC, area under receiver operating characteristic curve; EGFR, epidermal growth factor receptor; FNA, fine-needle aspiration; NSCLC-NOS, non-small cell lung cancer–not otherwise specified; PD-L1, programmed death ligand-1; ref., reference.